Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 2/20 | 0.30 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323173 | 0.85 | LTA4H (0.37) | LTA4HMMP2MMP3BMP1MMP1 | |
| SCHEMBL3319461 | 0.80 | ATM (0.39) | MMP2MMP3BMP1MMP1MMP13 | |
| SCHEMBL3320499 | 0.79 | MMP1 (0.41) | MMP2MMP3BMP1MMP1MMP13 | |
| SCHEMBL3320496 | 0.79 | MMP1 (0.41) | MMP2MMP3BMP1MMP1MMP13 | |
| SCHEMBL3320624 | 0.78 | ALDH1A1 (0.39) | — | |
| SCHEMBL3319795 | 0.70 | LTA4H (0.45) | LTA4HMMP2MMP3MMP1CTSK | |
| SCHEMBL3319798 | 0.70 | LTA4H (0.45) | LTA4HMMP2MMP3MMP1CTSK | |
| SCHEMBL14492873 | 0.70 | LTA4H (0.53) | LTA4HMMP2MMP3BMP1MMP1 | |
| SCHEMBL14492870 | 0.67 | MMP1 (0.37) | LTA4HMMP2MMP3BMP1MMP1 | |
| SCHEMBL14492875 | 0.65 | MMP2 (0.52) | LTA4HMMP2MMP3BMP1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
| US-7186719-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | LTA4H 2125/4885MMP2 1579/4885MMP3 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.